Cargando…

Immune Response following BNT162b2 mRNA COVID-19 Vaccination in Pediatric Cancer Patients

SIMPLE SUMMARY: Children with cancer experience a more severe SARS-CoV-2 infection and more often die due to COVID-19 than their healthy peers. Vaccination against SARS-CoV-2 is therefore recommend in children with cancer but little is known about their immune response following vaccination. With th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmidt, K. L. Juliëtte, Dautzenberg, Noël M. M., Hoogerbrugge, Peter M., Lindemans, Caroline A., Nierkens, Stefan, Smits, Gaby, Van Binnendijk, Rob S., Bont, Louis J., Tissing, Wim J. E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177402/ https://www.ncbi.nlm.nih.gov/pubmed/37174028 http://dx.doi.org/10.3390/cancers15092562

Ejemplares similares

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Central serous chorioretinopathy following the BNT162b2 mRNA vaccine
por: Hanhart, J., et al.
Publicado: (2022)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Addendum: Systems vaccinology of the BNT162b2 mRNA vaccine in humans
por: Arunachalam, Prabhu S., et al.
Publicado: (2023)

Myopericarditis After BNT162b2 mRNA Vaccination With Incidental Intramyocardial Bridging
por: Elghazal, Mohamed, et al.
Publicado: (2023)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
por: Thompson, Mark G., et al.
Publicado: (2021)

Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
por: Dickerman, Barbra A., et al.
Publicado: (2021)

BNT162b2 mRNA COVID-19 Vaccine: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
por: Terashima, Takeshi
Publicado: (2021)

Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
por: Gouda, Wesam, et al.
Publicado: (2022)

Bilateral anterior uveitis after BNT162b2 mRNA vaccine: Case report
por: Duran, M.
Publicado: (2022)

Systems biological assessment of human immunity to BNT162b2 mRNA vaccination
por: Arunachalam, Prabhu S., et al.
Publicado: (2021)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
por: Payne, Rebecca P., et al.
Publicado: (2021)

DIAPHRAGMATIC PARALYSIS FOLLOWING SECOND DOSE OF THE BNT162B2 MRNA COVID-19 VACCINE
por: PRUDENTI, JOHN A, et al.
Publicado: (2022)

Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability
por: Graydon, Elizabeth K., et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
por: Muik, Alexander, et al.
Publicado: (2022)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands
por: van den Hoogen, Lotus Leonie, et al.
Publicado: (2022)

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
por: Cocomazzi, Giovanna, et al.
Publicado: (2021)

Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
por: Felices-Farias, Jose Manuel, et al.
Publicado: (2022)

What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
por: Silvestris, Nicola
Publicado: (2021)

Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
por: June Choe, Young, et al.
Publicado: (2022)

Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
por: Felices-Farias, Jose Manuel, et al.
Publicado: (2022)

Hemophagocytic Lymphohistiocytosis Following BNT162b2 mRNA COVID-19 Vaccination
por: Lin, Ting-Yu, et al.
Publicado: (2022)

Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine
por: Juddoo, Vanessa, et al.
Publicado: (2022)

Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccine
por: Ramírez-García, Almudena, et al.
Publicado: (2021)

BNT162b2 mRNA Vaccine Interference with Co-Administration of Tdap Vaccine
por: Chilimuri, Sridhar, et al.
Publicado: (2021)

Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents
por: Mansanguan, Suyanee, et al.
Publicado: (2022)

Characterization of BNT162b2 mRNA to Evaluate Risk of Off-Target Antigen Translation
por: Patel, Himakshi K., et al.
Publicado: (2023)

Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022)

2349. Natural Killer Cells and BNT162b2 mRNA Vaccine Reactogenicity and Durability
por: Graydon, Elizabeth K, et al.
Publicado: (2023)

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
por: Mevorach, Dror, et al.
Publicado: (2021)

BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers
por: Benenson, Shmuel, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Severe hyponatraemia with cerebral oedema after Pfizer BNT162b2 mRNA vaccination against COVID-19
por: Dharma, J.F.M., et al.
Publicado: (2023)

BNT162b2, mRNA-1273, et EMA : une procédure qui roule
por: Dalmat, Yann-Mickael
Publicado: (2021)

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Barda, Noam, et al.
Publicado: (2021)

The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273
por: Markewitz, Robert, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uvhph2kcp9umsi3coa67ie4msu